subscribeSubscribe
Ibrutinib Plus Chemoimmunotherapy Fails to Improve PFS in Pretreated FL, MZL

Ibrutinib Plus Chemoimmunotherapy Fails to Improve PFS in Pretreated FL, MZL
Caroline Seymour ONCLIVE
20 Jun 2023
Share Share
Lurbinectedin/Doxorubicin Comparable to Standard of Care for SCLC, But Safer

Lurbinectedin/Doxorubicin Comparable to Standard of Care for SCLC, But Safer
ONCLIVE
10 Sep 2021
Share Share
Teva to produce children`s chemo drug again

Teva to produce children`s chemo drug again
Eric Palmer FIERCE PHARMA
15 Nov 2019
Share Share
Pfizer scrambles to fill void after Teva stops making chemo drug

Pfizer scrambles to fill void after Teva stops making chemo drug
Eric Palmer FIERCE PHARMA
16 Oct 2019
Share Share
CASI Pharma Announces Launch of EVOMELA® (melphalan injection) in China

CASI Pharma Announces Launch of EVOMELA® (melphalan injection) in China
PR NEWSWIRE
12 Aug 2019
Share Share
Spectrum Pharmaceuticals sells marketed drugs to Aurobindo subsidiary for up to $300M

Spectrum Pharmaceuticals sells marketed drugs to Aurobindo subsidiary for up to $300M
Alaric Dearment MEDCITY NEWS
18 Jan 2019
Share Share
Seattle Genetics Announces results of Broad ADCETRIS® (Brentuximab Vedotin)

Seattle Genetics Announces results of Broad ADCETRIS® (Brentuximab Vedotin)
BUSINESSWIRE
01 Nov 2018
Share Share
Celltrion & Teva Announce FDA ODAC Recommends CT-P10 Approval

Celltrion & Teva Announce FDA ODAC Recommends CT-P10 Approval
BUSINESSWIRE
11 Oct 2018
Share Share
AbbVie, J&J’s Imbruvica fails to target in B-Cell lymphoma trial

AbbVie, J&J’s Imbruvica fails to target in B-Cell lymphoma trial
Selina McKee PHARMA TIMES
12 Jul 2018
Share Share
AbbVie Stock Drops After Disappointing Clinical Trial Update

AbbVie Stock Drops After Disappointing Clinical Trial Update
Mark Terry BIOSPACE
12 Jul 2018
Share Share